SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of... Read More

Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa Additional Poster Underscores the Need for Non-Oral Treatment Options Given the Prevalence of Pre-Existing Gastrointestinal Disorders Among Those Prescribed Trudhesa SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission... Read More

Trudhesa ® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering... Read More

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. “Michael brings an outstanding track record of executive leadership in... Read More

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference... Read More

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were Well-Tolerated with Limited Treatment-Emergent Adverse Events Reported SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals... Read More

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and... Read More

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa ® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual... Read More

Trudhesa ® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies... Read More

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update. To access the... Read More

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March: 43rd Annual TD Cowen Health Care Conference : Adrian Adams, Chairman and Chief Executive Officer,... Read More

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescriptions from Q2 2022 to Q4 2022 Following Expansion of Sales Force SEATTLE, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a... Read More

Trudhesa ® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL) , a commercial-stage pharmaceutical company developing transformative... Read More

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4 th Annual Immunology and Neurology Day on Tuesday, November 15,... Read More

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update. To access the live... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that the Company will participate in two upcoming investor conferences in September: H.C. Wainwright 24th Annual Global Investment Conference: Adrian Adams, Chairman and... Read More

Trudhesa ® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity Company Reiterated Prescription Guidance Range of 70-85K TRx’s for 2022 Initiated Proof-of-Concept Study for INP105 in Autism Spectrum Disorder Impel to Host Investor Conference Call Today at 8:30 A.M. ET Impel... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, August 15, 2022, at 8:30 a.m. ET to report its second quarter 2022 financial results and provide a business update. To access the... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, and John Leaman, M.D., Chief Financial and Business Officer, will participate in a fireside chat at the 2022... Read More

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the first subject has been dosed in a Phase 2a proof-of-concept study of... Read More

Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa Two Additional Analyses Demonstrate Trudhesa Efficacy Regardless of Current Preventive Therapies or Prior Acute Treatments Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00... Read More

Trudhesa ® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022 Financing Agreement with Oaktree Capital Extends Cash Runway into 2024 Impel to Host Investor Conference Call Today at 8:30 A.M. ET Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at... Read More

Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, May 16, 2022, at 8:30 a.m. ET to report its first quarter 2022 financial results and provide a business update. The conference call... Read More

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is changing its name to Impel Pharmaceuticals. This new name reflects the ongoing corporate and strategic transformation of the Company and the use of its proprietary Precision Olfactory Delivery (POD ® ) technology to treat... Read More

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022. Impel is celebrating its one-year... Read More

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14,... Read More

Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study for Autism Spectrum Disorder in First Half of 2022 Recent $100 million Royalty and Debt agreement provides a projected cash runway into 2024 Impel To Host Investor Conference Call Today At 8:30 A.M. ET Impel NeuroPharma (NASDAQ:... Read More

New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers Efficacy of Trudhesa After Variety of Acute Therapies Post Hoc Pivotal Trial Data Indicates that Trudhesa Use Was Associated with Reduction in Disability and Frequency of Monthly Migraine Attacks Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for... Read More

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update. The... Read More

Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ $100 million in gross proceeds to be funded at close, extending estimated corporate cash runway into 2024 Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central... Read More

Trudhesa ™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable Trudhesa ™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022 Impel NeuroPharma... Read More

Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted Focus on High-Prescribing Neurologists, Headache Specialists and Primary Care Physicians Increased Cash Position and Extended Runway into 2023 with Follow-on Equity Offering of 3.45 Million Shares Valued at $51.8 Million Company... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that Adrian Adams, Chairman and CEO, will participate in a fireside chat at the Guggenheim Securities 3 rd Annual Neuro/Immunology Conference on Tuesday, November 16,... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that management will host a live webcast on Monday, November 15, 2021 at 8:30 a.m. ET to report its third quarter 2021 financial results and provide a business... Read More

Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil's proprietary workflow to enhance the patient's access to therapy. Trudhesa is... Read More

Carepoint Pharmacy announces that it will partner with Impel NeuroPharma, Inc. (NASDAQ: IMPL) to begin dispensing Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. Trudhesa, approved by the U.S. Food and Drug Administration (FDA) on September 2, 2021 , uses Impel's proprietary Precision Olfactory Delivery (POD®) technology to gently... Read More

Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space Trudhesa is Available Through Trudhesa Direct™, Which Will Provide Hassle-Free Prescribing, Savings and Home Delivery Facilitated by Digital Pharmacy Partners Carepoint Pharmacy and Phil, Inc. Eligible, Commercially-Insured Patients Will Be... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares of common stock are... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition,... Read More

TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space TRUDHESA Is Well Tolerated and Delivers Rapid, Sustained and Consistent Symptom Relief for the Acute Treatment of Migraine Commercial Launch of TRUDHESA is Planned for Early October 2021 Impel to Host Investor Call on Tuesday, September 7, 2021 at 8:30 a.m. ET Impel NeuroPharma,... Read More

TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank Impel to Host Investor Conference Call Today at 8:30... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced it will host a live webcast on Monday, August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021 financial results and provide a business update. A live... Read More

Study Shows TRUDHESA ™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One Third of Patients Experienced Pain Freedom and Two Thirds Had Pain Relief Two Hours Following TRUDHESA ™ Administration Among the 38 Percent of Patients Who Self-Reported Two-Hour Pain Freedom for Their First TRUDHESA™- Treated Attack, only 7.1 Percent and 14.3 Percent of... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that Adrian Adams, chief executive officer, will present on a panel titled “For Headaches THIS Big – The Evolution of Migraine Therapeutic Landscape” at the 2021... Read More

Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In... Read More

Impel NeuroPharma, Inc. (Impel), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced the closing of a $50 million debt facility with Oxford Finance LLC and Silicon Valley Bank, of which the first $20 million was funded at closing. “This strategic debt... Read More

Impel NeuroPharma , a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET. A live webcast, if recorded,... Read More

Completed successful IPO raising approximately $80.0 million in gross proceeds NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD ®... Read More

Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including Nausea and Nasal and Cardiovascular Safety as a Promising Potential New Option for the Treatment of Acute Migraine Attacks Impel NeuroPharma , a late-stage biopharmaceutical company focused on the development and... Read More

Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut. The new initiative, available on reroutemigrainerelief.com , educates the public about the complex nature of migraine, including the brain/gut connection,... Read More